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We compared breast cancer mortality rates in the period 1985–2000 in two areas of the province of Florence, Italy, where breast
cancer screening programmes started in the 1970s (early screening (ES) area) and in 1990s (late screening (LS) area). The overall
age-standardised mortality decreased in the whole period by 40.9% in the ES area (Po0.001), and by 11.3% in the LS area
(P¼0.030). Significant decreases in the ES area were detected in groups aged 45–54 years (61.1%; P¼0.018) and 65–74 years
(44.7%; P¼0.049), whereas in the LS area no significant decrease was detected in any age group. The relatively low compliance in the
first years of the programme in both areas, and the long enrolment period in the LS area could have reduced the effect on mortality.
Our findings suggest that the drop in mortality in the ES area (41%) could be explained by both service screening and better care.
The slight decrease in mortality in the LS area (11%) could be mainly due to better care. A reduction of about 30% is attributable to
screening in the ES area over the period 1985–2000.
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Mammographic screening has been shown to reduce breast cancer
mortality rates (Vainio and Bianchini, 2002). Several studies in
northern European countries (Hermon and Beral, 1996; Hakama
et al, 1997; Van den Akker-van Marle et al, 1999; Blanks et al, 2000;
Jonsson et al, 2001; Botha et al, 2003; Otto et al, 2003; Tabar et al,
2003) have reported a decrease in breast cancer mortality where
nationwide screening programmes have been implemented. There
has, however, been considerable debate concerning the relative
contributions of screening and of improved therapy to the
observed trends (Carnon et al, 1996; Blanks et al, 2000; Peto
et al, 2000).
At the beginning of the 1970s in 23 rural municipalities of the
province of Florence, Italy (early screening area (ES area) among
about 70000 resident women aged 25 or over, 18% of women of the
province, based on 1991 Census), a mammographic screening
programme was started; until 1989, women in the 40–69 year age
group were invited, whereas from that year onwards the target
population was restricted to age group 50–69 years. The number
of mammograms performed in the ES area was 8000–9000 per
year. The efficacy of the programme on breast cancer mortality in
the ES area has been evaluated for the period 1977–1984 by means
of case–control studies (Palli et al, 1986, 1989), and by using early
indicators of efficacy (Paci et al, 1990). After 1990, when the
screening for women aged 50–69 years started in the rest of the
province, including the city of Florence (late screening area: LS
area), the number of mammograms in the whole province
increased to 28000–29000 per year (Barchielli et al, 1999).
In this study, we have compared breast cancer mortality rates in
the period 1985–2000 in the ES and LS areas.
MATERIALS AND METHODS
Sources of data
Data on breast cancer mortality for the period 1985–2000 were
obtained from the Tuscan Regional Mortality Register (Chellini
et al, 2002), which collects death certificates of the residents of
Tuscany. Incident breast cancer cases for the period 1985–1999
were obtained from the Tuscan Cancer Register, a member of the
International Association of Cancer Registries (Parkin et al, 2002).
Statistical analysis
Adjusted mortality and incidence rates using direct standardisa-
tion to the European Standard Population, and age-specific (35–
44, 45–54, 55–64, 65–74, 75–84 and X85 years) incidence and
mortality rates with 95% confidence intervals (95% CI) were
calculated.
In order to calculate the estimated percent change (EPC) in
rates for the whole period of observation, trends in mortality
and incidence based on annual data were examined using
a log-linear regression model, and the year of death as a
continuous variable.
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The age-adjusted mortality rate in the ES area (Figure 1) was 22.4
per 100000 women in 1985 (95% CI: 13.6–31.2; 27 deaths), 31.8 in
1991 (95% CI: 21.0–42.6; 38 deaths) and then decreased to 10.9 in
2000 (95% CI: 5.4–16.5; 19 deaths). In the LS area, the
corresponding age-standardised mortality rates were more stable
with only a slight decrease over time: in 1985 30.1 per 100000
women (95% CI: 25.5–34.7; 186 deaths); 27.7 in 2000 (95% CI:
23.3–32.1; 190 deaths). In the ES area, age-specific mortality rates
decreased steadily from 1985 to 1986 until 1999–2000 in all age
groups, except for 85þ age group (Figure 2). The age-specific
rates in the LS area were more stable (Figure 3).
In the ES area, incidence was 76.9 per 100000 women in 1985
(95% CI: 59.6–94.1), 96.7 in 1989 (95% CI: 77.6–115.8), 62.5 in
1993 (95% CI: 47.9–77.1) and 110.6 in 1999 (95% CI: 90.8–130.4).
In the LS area, incidence rates were higher: 91.1 per 100000 women
in 1985 (95% CI: 82.6–99.6), 112.1 in 1993 (95% CI: 102.9–121.4)
and 113.9 in 1999 (95% CI: 104.5–123.4).
In addition to visual inspection, we measured EPCs in rates over
the whole period (Table 1). In the period 1985–2000, the overall
age-standardised mortality decreased by 40.9% in the ES area
(Po0.001), and by 11.3% in the LS area (P¼0.030). Significant
decreases in the ES area were detected in age groups 45–54 years
(61.1%; P¼0.018) and 65–74 years (44.7%; P¼0.049). In the 75–
84 age group, the decrement was 45.2% (P¼0.053). In the LS area,
no significant decreases were detected in any age group.
In the period 1985–1999, the overall age-standardised incidence
increased by 12.9% in the ES area (P¼0.190), and by 14.2% in the
LS area (Po0.001) (Table 1). In the ES area, no significant
increases or decreases were detected in any age groups; in the LS
area, where the prevalence screening was carried out in the period
1990–1994, significant increases were detected in groups aged 55–
64 years (21.0%; P¼0.009) and 85 years and over (45.1%;
P¼0.012).
DISCUSSION
Decreases in breast cancer mortality have been variously reported
following the introduction of mammographic screening on a
regional level (Tornberg et al, 1994; Quinn and Allen, 1995; Garne
et al, 1997; Barchielli and Paci, 2001; Broeders et al, 2001; Tabar
et al, 2001; Duffy et al, 2002). Randomised prospective trials
indicate that benefits in terms of cumulative breast cancer
mortality start to emerge 4–10 years after randomisation
(Nystro ¨m et al, 2002). We observed a similar trend in the
mortality rates in the two areas up to 1993, although the mortality
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Figure 1 Age-adjusted (European population) breast cancer mortality rates in the ES area and in the LS area. Period 1985–2000, 3-year moving averages.
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Figure 2 Age-specific mortality rates in the period 1985–2000 in the ES
area of the province of Florence, Italy.
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Figure 3 Age-specific mortality rates in the period 1985–2000 in the LS
area of the province of Florence, Italy.
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Afterwards a marked fall occurred in ES area, whereas only a slight
decrease was observed in the LS area. The relatively low
compliance in the first years of the programme in both areas
(about 55%) and the long enrolment period (on average 2.5 years)
in the LS area (Paci et al, 2002a,b) could have diluted the effect so
that a decrease in mortality rates was observed only after a longer
interval.
Our findings suggest that the drop in mortality in the ES area
(41%) could be explained by both service screening and better
care. The slight decrease in mortality in the LS area (11%) could be
explained by better care, while service screening of the period
1990–2000 in the LS area could have been responsible for only a
small number of deaths occurring in the target population. In fact,
it has been estimated that in the city of Florence, the breast cancer
mortality reduction at ages 50–74 years attributable to screening
was 3.2% over the period 1990–1999 (Paci et al, 2002a). Thus,
allowing a 11% reduction due to better care, a reduction of about
30% (41–11%) is attributable to screening in the ES area over the
period 1985–2000. These findings are consistent with the mortality
reduction of about 25% in screened populations shown by
randomised trials (Vainio and Bianchini, 2002).
The decrease in mortality at ages 45–54 years in the ES area
could be related to the involvement in mammographic screening of
women aged 40–49 years in the ES area until 1993. In 1985–1993,
33% of mammograms in the ES area (about 2700 per year) were
performed on women aged 40–49 years. No mortality reduction
would be expected from screening in the younger age group (35–
44 years) or in the 85 years and over age group.
In evaluating these results, it must be borne in mind that the
ES area, where the incidence rates were lower, was a less
urbanised area during the period of observation. The significant
increase in incidence recorded only in the LS area (of 14.2%),
particularly in women aged 55–64 years (21.0%), could be
explained by earlier detection. Increases in incidence have been
recorded in other Western countries in relation to screening
(Quinn and Allen, 1995; Garne et al, 1997; Persson et al, 1998; Chu
et al, 1996; Rostgaard et al, 2001). In the ES area, no significant
increase in incidence was detected. It is likely that an increase in
incidence in the ES area should have occurred in the 1970s, as a
result of screening.
Incidence trends in the ES and LS areas do not seem to explain
the observed differences in mortality rates during the study period.
The present results seem to confirm that service screening can
reduce breast cancer mortality rates.
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